DDBy Calypso Research7 min read

DuPont de Nemours (DD) Q4 2025 Earnings Analysis

DuPont's Revenue Takes a Dive but Stock Soars 4.9% - Chemistry at Play

Key Takeaways

DuPont de Nemours (DD) reported Q4 2025 earnings with revenue of $1.7B, representing a -45.2% year-over-year change. The stock moved +4.9% on earnings day.

The bull case: Execution on productivity, innovation-led mix upgrade, and disciplined healthcare/water M&A drives steady mid-single-digit organic growth, expanding margins, and a valuation re-rating away from chemicals toward higher-quality industrial/healthcare peers.

The bear case: Macro and China industrial softness, lingering construction and shelter headwinds, and potential overreach on M&A in high-multiple niches could cap growth, compress returns on capital, and keep the stock trading on a more cyclical chemicals multiple.

Financial Highlights

  • Revenue: $1.7B (-45.2% YoY)
  • Gross Profit: $527M (31.1% margin, -0.5% YoY)
  • Operating Income: $227M (13.4% margin, -2.1% YoY)
  • Net Income: $-126M
  • TTM Revenue: $11.1B

Stock Performance

  • Earnings Day Move: +4.9%
  • Year-to-Date: +22.5%
  • 1-Year Return: +46.3%
  • vs. S&P 500 (since earnings): +19.9%
  • vs. Nasdaq (since earnings): +22.7%

View live DD data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from DuPont de Nemours's Q4 2025 earnings call:

Industrial & Shelter Cycle: How Durable Is the Recovery and What’s the 2026 Cadence?

Sentiment: Positive

"We've seen nice order pickup as we exited the year and went into Q1... all the businesses kind of in that industrial technology space are doing nicely and seeing kind of the short cycle recovery that other [peers] have been pointing to." — Lori Koch
"When we start off 2026, I would tell you that we expect [shelter] to be slightly down as we start the year... we do expect slight improvement as we go through the course of the year... that gets you to the overall flat for the year." — Lori Koch

Margin Expansion & Productivity: Is There Upside to the 60–80 bps Target?

Sentiment: Positive

"When you look at our guidance for 2026, we have at least 20 basis points of margin expansion coming from productivity... you'll see that continue as we go into 2026 and we'll continue to drive that as we move through the three-year period." — Antonella Franzen
"When you kind of look at the activity in the fourth quarter, I would point more towards... a bit of mix... as well as a strong push relative to productivity... I would say, you're not really yet seeing the benefits of 80/20... the benefits of that, I would say, are to come." — Lori Koch

Capital Allocation, Aramis Proceeds & M&A vs. Buybacks

Sentiment: Positive

"It will be about $1 billion on a net tax basis. Keep in mind, we've already deployed about half of that with the $500 million ASR... which is enabling about 2.5% EPS growth for us this year." — Lori Koch
"I wouldn't say there's a specific amount earmarked towards an M&A deal or a specific amount earmarked towards share repurchases. We'll continue to look at both... and deploy capital in the best interest of our shareholders as we move forward." — Antonella Franzen

Healthcare & Water Growth Sustainability (Including China & Destocking)

Sentiment: Positive

"We are seeing a slower start in China with respect to overall growth within the water, and it's primarily stemming from just the reduced industrial production in the region... we'll start in the low single digits in China water and then we'll ramp into the back half to get overall to that mid-single-digit." — Lori Koch
"The destock was behind us in 2025, so we've continued to see normalized inventory levels across both [healthcare and water] businesses." — Lori Koch

Innovation, Vitality Index & Structural Pricing Power

Sentiment: Positive

"If we look at the margin profile of those products that comprise new product sales, it is higher than the overall margin of the company... our 30% vitality index... we have about 145 basis points of margin lift from those products that are introduced in the past five years." — Lori Koch
"Going forward, [we] would expect to see structural price lift... in 2026, our 3% organic is primarily volume, but underneath that, there is some price in some of the businesses... there is an opportunity to drive structural price in most of the businesses in our portfolio." — Lori Koch

Bull Case

Execution on productivity, innovation-led mix upgrade, and disciplined healthcare/water M&A drives steady mid-single-digit organic growth, expanding margins, and a valuation re-rating away from chemicals toward higher-quality industrial/healthcare peers.

Bear Case

Macro and China industrial softness, lingering construction and shelter headwinds, and potential overreach on M&A in high-multiple niches could cap growth, compress returns on capital, and keep the stock trading on a more cyclical chemicals multiple.

Looking Ahead

With revenue declining -45.2% year-over-year, investors will be watching for signs of a turnaround at DuPont de Nemours, particularly around industrial & Shelter Cycle: How Durable Is the Recovery and What’s the 2026 Cadence?. With operating margins at 13.4%, margin trends will remain a focal point. The market's positive reaction on earnings day suggests confidence in management's direction, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was DuPont de Nemours's revenue in Q4 2025?

DuPont de Nemours reported Q4 2025 revenue of $1.7B, representing a -45.2% year-over-year change.

Did DuPont de Nemours beat earnings expectations in Q4 2025?

The stock rose +4.9% on earnings day, suggesting the results met or exceeded market expectations. The current bull case centers on: Execution on productivity, innovation-led mix upgrade, and disciplined healthcare/water M&A drives steady mid-single-digit organic growth, expanding margins, and a valuation re-rating away from chemicals toward higher-quality industrial/healthcare peers.

What is the bull case for DD stock?

The bull case for DD centers on: Execution on productivity, innovation-led mix upgrade, and disciplined healthcare/water M&A drives steady mid-single-digit organic growth, expanding margins, and a valuation re-rating away from chemicals toward higher-quality industrial/healthcare peers.

What is the bear case for DD stock?

The bear case for DD centers on: Macro and China industrial softness, lingering construction and shelter headwinds, and potential overreach on M&A in high-multiple niches could cap growth, compress returns on capital, and keep the stock trading on a more cyclical chemicals multiple.

How has DD stock performed since its Q4 2025 earnings?

DD moved +4.9% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +19.9% since earnings. Year-to-date, the stock has returned +22.5%.

Browse all 400+ earnings reports →

Learn More

Analyze DD in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for DuPont de Nemours and 400+ other stocks, explore the full platform.

Open DD on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.